Article · Wikipedia archive · Last revised Jun 24, 2026

Cycloproscaline

Cycloproscaline (CP), also known as 4-cyclopropoxy-3,5-dimethoxyphenethylamine (4-cPrO-3,5-DMPEA), is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is the homologue of mescaline in which the 4-methoxy group has been replaced with a 4-cyclopropoxy group. The drug has a dose of 60 mg or more orally and a duration of 6 hours or more, but has not been fully evaluated. It is a low-potency full agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors such as the serotonin 5-HT1A and 5-HT2C receptors. The drug's chemical synthesis has been described. Cycloproscaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013. Its pharmacology was studied in greater detail in 2021. The drug is not a controlled substance in Canada as of 2025.

Last revised
Jun 24, 2026
Read time
≈ 1 min
Length
260 w
Citations
15
Source
Wikipedia ↗
Cycloproscaline
Clinical data
Other namesCP; 4-Cyclopropoxy-3,5-dimethoxyphenethylamine; 4-cPrO-3,5-DMPEA
Routes of
administration		Oral12
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action≥6 hours12
Identifiers
  • 2-(4-cyclopropyloxy-3,5-dimethoxyphenyl)ethanamine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H19NO3
Molar mass237.299 g·mol−1
3D model (JSmol)
  • COC1=CC(=CC(=C1OC2CC2)OC)CCN
  • InChI=1S/C13H19NO3/c1-15-11-7-9(5-6-14)8-12(16-2)13(11)17-10-3-4-10/h7-8,10H,3-6,14H2,1-2H3
  • Key:VRTSLAVKWTZKIT-UHFFFAOYSA-N

Cycloproscaline (CP), also known as 4-cyclopropoxy-3,5-dimethoxyphenethylamine (4-cPrO-3,5-DMPEA), is a psychedelic drug of the phenethylamine and scaline families related to mescaline.12 It is the homologue of mescaline in which the 4-methoxy group has been replaced with a 4-cyclopropoxy group.12 The drug has a dose of 60 mg or more orally and a duration of 6 hours or more, but has not been fully evaluated.12 It is a low-potency full agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors such as the serotonin 5-HT1A and 5-HT2C receptors.2 The drug's chemical synthesis has been described.1 Cycloproscaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013.1 Its pharmacology was studied in greater detail in 2021.2 The drug is not a controlled substance in Canada as of 2025.3

See also

See also

References

References

  1. Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 706, 713–716. ISBN 978-3-03788-700-4. OCLC 858805226.
  2. Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021). "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology. 12 794254. doi:10.3389/fphar.2021.794254. PMC 8865417. PMID 35222010.
  3. "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
External links